問卷
此案目前為暫存狀態
編修至YYYY/MM/DD
不開放編輯功能
Find Division/Department
National Taiwan University Hospital
All Location
All Division/Department
篩選
Developmental Phase
Phase I
Phase I/II
Phase II
Phase II/III
Phase III
Phase IV
Others
Trial Status
Not yet recruiting
Active
Completed
Recruitment Status
Recruiting
Terminated
Stop recruiting
Suspended
Study ended
Trial scale
Multi-Regional Multi-Center
Taiwan Multiple Center
Taiwan Single Center
The expected start time interval of the test
Trial Applicant
Hospital/Foundation
Pharmaceutical/Biopharmaceutical company
Contract Research Organization
Important Roles
Asia Regional PI
Taiwan National PI
Chairman/Global PI
Steering Committee
Advisory board
None
Audit by Sponsors/CRO
Sponsors
CRO
Investigator-initiated trial(IIT)
Yes
Filters
下載
2021-04-01 - 2022-06-30
Condition/Disease
Test Drug
Participate Sites4Sites
Terminated4Sites
2019-04-01 - 2022-12-31
Participate Sites8Sites
Recruiting1Sites
Terminated7Sites
non-squamous non-small cell lung cancer
Durvalumab、Tremelimumab
Recruiting8Sites
Division of General Internal Medicine
2018-10-01 - 2022-12-31
Nasopharyngeal Carcinoma
Pembrolizumab (MK3475)
Recruiting5Sites
Terminated3Sites
2018-09-01 - 2022-12-31
Hepatocellular Carcinoma (HCC)
nivolumab﹝Opdivo﹞/ ipilimumab ﹝Yervoy﹞
Participate Sites9Sites
2013-12-01 - 2016-05-31
Participate Sites2Sites
Terminated2Sites
2019-07-01 - 2021-12-23
Primary Breast Cancer
Ibrance
Recruiting3Sites
Terminated1Sites
2019-06-01 - 2021-06-11
HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer
Tesetaxel
2021-12-04 - 2023-12-31
Participate Sites10Sites
Recruiting10Sites
2007-05-01 - 2009-04-30
Terminated9Sites
全部
